The implications of measuring lipoprotein(a) in clinical practice

Authors

  • Mahmoud Barbir Harefield Hospital, part of Guy's and St Thomas' NHS Foundation Trust, UK
  • Alison Pottle Harefield Hospital, part of Guy's and St Thomas' NHS Foundation Trust, UK
  • Stefan R. Bornstein University Hospital Carl Gustav Carus Dresden, Fetscherstraße 74, 01307 Dresden, Germany

DOI:

https://doi.org/10.21542/gcsp.2024.40

Abstract

Lipoprotein(a) (Lp(a)) is a well-recognized causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis.  There are ongoing challenges with screening and management in primary and secondary prevention; however, future recommendations for clinical practice await the outcomes of clinical trials that are in progress.

Downloads

Published

2024-08-29

Issue

Section

Editorial